Steven Cohen Amylyx Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 4,536,266 shares of AMLX stock, worth $37.2 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
4,536,266
Previous 916,966
394.7%
Holding current value
$37.2 Million
Previous $3.25 Million
795.78%
% of portfolio
0.07%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding AMLX
# of Institutions
144Shares Held
76MCall Options Held
212KPut Options Held
40.6K-
Adage Capital Partners Gp, L.L.C. Boston, MA8.8MShares$72.2 Million0.1% of portfolio
-
Perceptive Advisors LLC New York, NY7.9MShares$64.9 Million2.22% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$48.8 Million7.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$36.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX3.26MShares$26.8 Million8.47% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $481M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...